首页> 外文期刊>VASA: Zeitschrift fuer Gefarsskrankheiten. Journal for vascular diseases >Endovascular treatment of post-thrombotic and non-thrombotic iliofemoral venous outflow obstructions with self-expanding nitinol stents
【24h】

Endovascular treatment of post-thrombotic and non-thrombotic iliofemoral venous outflow obstructions with self-expanding nitinol stents

机译:血管内治疗血浆和非血栓形成髂骨外静脉暴露梗阻与自膨胀硝基吲哚支架

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: The aim of the study was to investigate venous patency and clinical outcomes for endovascular treatment of iliofemoral venous obstruction in patients with post-thrombotic syndrome (PTS) and non-thrombotic iliac vein lesion (NIVL) with dedicated self-expanding nitinol stents. Patients and methods: Data were collected from the prospective Swiss Venous Stent Registry, enrolling consecutive patients with a standardized follow-up procedure since January 2008. Patency was evaluated by duplex sonography and clinical outcome by various scores including the Villalta score at baseline, three, six, and 12 months, and then annually after endovascular therapy. Results: Overall, 93 patients (64 PTS, 29 NIVL) were analysed. Mean follow-up time was 20 +/- 16 (range 3-70) months. A total of 11 (12 %) patients had a stent occlusion, all of which occurred in the PTS group, and 13 (14 %) patients had a symptomatic stent stenosis. Primary patency was 79 % (95 % CI 68-87 %) at 12 months and 72 % (95 % CI 59-82 %) at 24 months. In PTS patients, primary patency at 12 months was 75 % (95 % CI 61-84 %) vs. 89 % (95 % CI 63-97 %) in NIVL patients (p = 0.10). Secondary patency at 24 months was 94 % (95 % CI 84-98 %) in PTS and 100 % in NIVL, p = 0.19). Overall, 62 (67 %) patients were free from PTS at the latest follow-up with a Villalta score 5 points. Predictive factors for the loss of primary patency were stents placed below the inguinal ligament (OR 2.59, 95 % CI, 0.99-6.84, p = 0.05). Conclusions: In symptomatic patients with chronic iliofemoral vein obstruction, endovascular therapy with self-expanding nitinol stents was associated with favourable patency rates and clinical improvement in the majority of patients.
机译:背景:该研究的目的是调查血管内患者血管内静脉阻塞患者血管静脉梗死患者血管内静脉阻塞(PTS)和非血栓性髂静脉病变(NIVL),具有专用的自膨胀硝基戊醇支架。患者和方法:从预期瑞士静脉支架注册处收集数据,自2008年1月以来,注册了标准化后续程序的连续后续程序。通过双面超声检查和各种分数的临床结果评估了Palenta评估,包括基线,三个,三个,六和12个月,然后每年在血管内治疗后。结果:总体而言,分析了93名患者(64分,29个NIVL)。平均随访时间为20 +/- 16(范围3-70)个月。总共11例(12%)患者具有支架闭塞,所有这些都发生在PTS组中,13例(14%)患者患有症状狭窄。在24个月内,12个月,初级通畅在12个月内为79%(95%CI 68-87%),72%(95%CI 59-82%)。在PTS患者中,12个月的原始通畅是NIVL患者中的75%(95%CI 61-84%),对89%(95%CI 63-97%)(P = 0.10)。 24个月的二级通用含量为94%(95%CI 84-98%),NIVL中1​​00%,P = 0.19)。总体而言,62名(67%)患者在最新随访中没有PTS,与Villalta得分& 5分。用于损失的主要通畅性的预测因素是放置在腹股沟韧带以下(或2.59,95%CI,0.99-6.84,P = 0.05)的支架。结论:在患有慢性Ilioforal静脉阻塞的症状患者中,具有自扩张Nitinol支架的血管内疗法与大多数患者的高密率和临床改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号